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Reactive oxygen species play critical roles in the development and
progression of diabetic nephropathy (DN). To evaluate the effect of antioxidant
therapy on renal damage, we investigated the effect of green tea catechin on
oxidative stress-induced renal cell damage in LLC-PK cells and DN induced by
subtotal nephrectomy plus streptozotocin injection in rats, Antioxidant
activities of 6 green tea catechins were evaluated by 1,1-diphenyl-2-
picrylhydrazyl (DPPH) radical scavenging activity test. Protective effect of (-)-
epigallocatechin 3-O-gallate (EGCG) as a representative tea catechin against
oxidative renal cell damage was measured in LLC-PK cells. EGCG showed the
strongest DPPH radical scavenging activity and protected renal epithelial LLC-
PK cells from oxidative damage in the dose-dependent manner. Hyperglycemia,
proteinuria and the elevated lipid peroxidation levels were reduced by EGCG
administration. The renal protein expressions related to diabetic nephropathy
such as iNOS, COX-2, NF-kB, phosphorylated IkB-a, TGF-b1 and ﬁbronectin
were signiﬁcantly decreased after EGCG treatment.
In conclusion, EGCG has beneﬁcial effects on DN by suppressing
hyperglycemia and related oxidative stress in kidney.nCorresponding author.
http://dx.doi.org/10.1016/j.krcp.2012.04.552229
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Depression is the most common psychiatric complication in patients
with end-stage renal disease (ESRD). Sarcopenia, deﬁned as loss of muscle
mass and strength, is expected to be associated with depression, because
both are closely linked to physical inactivity and functional impairment.
We investigated the association of sarcopenia with depression in patients
with ESRD. A total of 115 patients undergoing hemodialysis (HD) were
included in this study. Muscle mass was assessed by lean tissue index (LTI)
using portable whole body bioimpedance spectroscopy, and muscle
strength was measured with handgrip strength (HGS). Depression was
deﬁned as Beck Depression Inventory-II (BDI-II) score Z16. About 60% of
prevalent HD patients had depression. Compared to subjects without
depression, depressed patients had a higher prevalence of sarcopenia (45.5
vs. 8.2%, po0.001) and signiﬁcantly increased serum IL-6 and hs-CRP level.
However, (pre)albumin and body mass index (BMI) failed to correlate with
BDI-II. HGS and LTI had a consistent negative effect on BDI-II even after
adjusting other parameters including inﬂammation. In multivariate
analysis, lower , increased IL-6 and b2-microglobulin,and sarcopenia were
signiﬁcant predictors for depression; sarcopenia was most powerful [odds
ratio 9.01, 95% CI 3.60-12.22, p¼0.001]. In conclusion, the prevalence of
sarcopenia and depression was considerably high and and the presence of
sarcopenia was an important predictor for depression.
http://dx.doi.org/10.1016/j.krcp.2012.04.553230
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Nutrition care is complex and encompasses evaluation and correction of
protein-energy wasting plus many nutrition abnormalities such as
hyperphosphatemia, abdominal obesity, and risk factors of cardiovascular
disease. The purpose of this study was to test a nutritionally comprehensive
algorithm for feasibility and functionality in a diverse group of HD patients.
This was a prospective, observational study designed to test a nutrition
algorithm for 1) clinical feasibility; 2) logical progression; 3) ability to collect
data; and 4) effectiveness in improving outcomes. Patients included in this
study were enrolled by renal dietitians (RD) working in HD units based in ﬁvenCorresponding author.different countries. To select study subjects, RD were asked to screen and
consent patients in their facilities until 4 patients were identiﬁed as at
nutrition risk per the algorithm’s screening tool. All data were collected via
the algorithm including screening, assessment, nutrition related diagnosis,
etiology of the nutrition diagnosis, nutrition related barriers, nutrition focused
interventions, and outcome parameters. Statistics were performed using SPSS
vs 20.0 and signiﬁcance set at po0.05. One hundred patients, enrolled by 29
RD, were included in this analysis. The screening parameters that triggered an
‘‘at risk ﬂag’’ for more than 50% of the patients were: PTH, serum cholesterol
and unintentional weight loss. Of the patients with an albumin of o3.8 mg/dl
(37% of sample), 73% were given a nutritional diagnosis of insufﬁcient protein
intake. Overall, patients with insufﬁcient intake had signiﬁcantly lower serum
albumin concentrations at baseline than those who did not have this
(3.770.4 vs. 4.070.4, po0.05). Patients with a diagnosis of ‘‘high
phosphorus’’ had decreases in serum PTH (349.57184.5 to 201.77113.6,
p¼0.06) and phosphorus (from 6.571.0–5.371.9 mg/dl, p¼0.04) at the
three month data collection. This study is the ﬁrst of its kind to show that a
web-based, HD speciﬁc, nutrition algorithm is feasible and effective.
http://dx.doi.org/10.1016/j.krcp.2012.04.554231
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Whilst L-carnitine (LC) supplementation is recommended for the
treatment of EPO-resistant anemia, the extent of effectiveness has been
shown to vary considerably. Previous work by Reuter et al (2008)
demonstrated a signiﬁcant association between EPO-resistance and
carnitine pool composition; based on these ﬁndings, it is hypothesized that
patients who have a high EPO resistance index (ERI) are more likely to
respond to LC supplementation. Preliminary assessment of this hypothesis
was conducted as retrospective analysis, using prospectively-deﬁned
criteria, of data from 2 randomized, double-blind, placebo-controlled trials.
HD patients were administered LC (20 mg/kg/wk/dialysis i.v.) or placebo
for 24 weeks, with EPO dose and hemoglobin data assessed at Weeks 0, 12
& 24. Patients were classiﬁed as High (40.02 mg/kg/wk/gHb) or Low ERI
based on baseline data. Treatment effectiveness was analyzed using
%baseline ERI for all patients (Low ERI & High ERI) and for High ERI patients
only. 77 patients (38 LC/39 placebo) were included in the analysis, of which
22 (14 LC/8 placebo) were classiﬁed as High ERI. Analysis of all patient data
indicated no signiﬁcant differences between Week 0, 12 & 24 %baseline ERI
for neither the LC nor placebo groups, whereas analysis of High ERI patient
data indicated a signiﬁcant reduction in %baseline ERI at Week 12 & 24
compared to Week 0 (p¼0.004) for the LC treatment group, with no
signiﬁcant placebo treatment effect. Similarly, analysis of %baseline ERI
area-under-the-curve from 0–241weeks indicated no signiﬁcant treatment
effects when all patients were included in the analysis, whereas for High
ERI patients, signiﬁcantly lower values were demonstrated for LC vs
placebo (p¼0.016). These ﬁndings suggest that High ERI patients may
receive the most beneﬁt from LC supplementation. It is proposed that LC
treatment results in an improvement in CPT activity via normalization of
the LC/acylcarnitine ratio, thereby resulting in stabilization of the RBC
membrane and improvement in anemia. A randomized, double-blind,
placebo-controlled study is being conducted to investigate this further.
http://dx.doi.org/10.1016/j.krcp.2012.04.555232
EFFECT OF BRAZILIAN NUT SUPPLEMENTATION ON ANTIOXIDANT,
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Dietary intake of selenium (Se) plays an important role as an antioxidant and
anti-inﬂammatory agent due to its antioxidant properties and the richest
known food source of Se is the Brazilian nut, found in the Amazon region,
Brazil. The aim of this study was to evaluate the effect of the Brazilian nut
supplementation on oxidative stress and inﬂammation markers and lipid
stratus in HD patients. Forty HD patients (57.5% men, 53.3716.1yrs) were
